InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing treatments, primarily psychedelics like psilocybin, for diseases with unmet medical needs.
Throughout the interview, McKee discussed the company’s prospective patients and targeted ailments, the need for innovation in the psychedelics space and Tryp’s planned human clinical trials later this year.
“We’re here fundamentally to help patients. We’re also very interested in bringing new therapies to these patients. All these indications that we’re working in – specifically fibromyalgia, phantom limb syndrome and complex regional pain syndrome, and potentially others such as tinnitus, cluster headaches, TMJ and others – all these subcategories of chronic pain are areas where there is significant unmet medical need,” McKee said. “In other words, situations where patients aren’t properly served. We know that new chemistries and new solutions need to be brought to the table. There needs to be a broader set of tools that physicians can use to treat these patients.”
“We also see there is a great need to innovate around the specific dose and the specific route of administration. Drugs are delivered in a lot of different ways and, up to this point historically, psilocybin and most of the other chemistries in the psychedelics space have all been oral pills,” he said. “We know there are several ways to better control the dose and control the patient experience in their dissociative state as they are trying to enable the neuroplasticity of the brain to release some of the misfirings or misalignments that were there previously and get realigned in a much more productive way, which is what we think fundamentally that psychedelics do.”
“We’re excited to innovate around the route of administration and controlled dosing so that patients have the proper kind of experience that ultimately heals their particular illness. 2021 is going to be a year where we tee up our academic collaborations, and multiple Phase 2a clinical studies,” McKee said. “We anticipate having at least two Phase 2a clinical trials up and running this year, and potentially more based on the breadth of academic collaborations we have underway. That will set us up to potentially see signals of efficacy in these patient populations for the first time.”
Join InvestorBrandNetwork’s Stuart Smith and Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), as they discuss the company’s 2020 milestones, Tryp’s academic research collaborations and the backgrounds of the company’s management team members.
To hear the whole podcast and subscribe for future episodes, visit https://podcast.stock2me.com.
The latest installment of The Stock2Me Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit https://IBN.fm/TimeLine
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.